Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients.

•BPI-9016M is a c-Met/AXL inhibitor for advanced solid tumor treatment.•An LC-MS/MS method was developed to detect BPI-9016M and its metabolites in plasma.•The method was fully validated from whole blood collection to plasma analysis.•The method was applied for a first-in-human clinical trial in Chinese patients.•Plasma concentrations in hemolyzed sample could be reported normally by the method.